The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2025 | Advances in ADCs for lung cancer at WCLC 2025
Hidehito Horinouchi, MD, PhD, National Cancer Center Hospital, Tokyo, Japan, gives an overview of recent updates in antibody-drug conjugates (ADCs) for lung cancer. Whilst trial data of patritumab deruxtecan (HER3-DXd) and trastuzumab deruxtecan (T-DXd) have not met expectations, ABBV-040, which uses a novel payload, has shown a better balance of safety and efficacy, including reduced hair loss and sensory neuropathy. This interview took place at 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We have several ADCs provided late-phase trial results. So the HER3-DXd and also the T-DXd showed a little bit disappointing result this year. Even though the T-DXd has been approved in the EGFR space, there should be several struggles to have the better ADCs. Right now, we have several other ADCs showing such kind of a very great balance of safety and efficacy. One great example is the same antibody-based agent, ABBV-040, that they are using the same antibody and different payload, topo-1 inhibitors...
We have several ADCs provided late-phase trial results. So the HER3-DXd and also the T-DXd showed a little bit disappointing result this year. Even though the T-DXd has been approved in the EGFR space, there should be several struggles to have the better ADCs. Right now, we have several other ADCs showing such kind of a very great balance of safety and efficacy. One great example is the same antibody-based agent, ABBV-040, that they are using the same antibody and different payload, topo-1 inhibitors. In the ABBV-040 program, we experience that there is a very great, lower proportion of patients who experience hair loss. That means likewise, there is a benefit in the sensory neuropathy. Even the payload has some kind of safety issue about the hair loss. But when the antibody is conjugated better than the other agent, the safety profile can be reduced based on such kind of combination of the ADC.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
